熱門資訊> 正文
Emergent BioSolutions为口服悬浮液TEMBEXA获得价值1700万美元的合同修改
2025-09-15 20:54
- Emergent BioSolutions (NYSE:EBS) announced on Monday it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to supply TEMBEXA oral suspension.
- The contract modification follows the U.S. Food and Drug Administration’s recent approval of the manufacturing scale-up of TEMBEXA oral suspension.
- The company said the newly exercised contract modification to supply TEMBEXA builds upon the previously announced options from September 2024, and are all under Emergent’s existing 10-year contract.
- EBS +1.96% premarket to $8.3.
- Source: Press Release
More on Emergent Biosolutions
- Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally
- Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful
- Mpox in Africa is no longer a global health emergency, WHO chief says
- Emergent Biosolutions awarded $30 million contract modification for CYFENDUS
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
